Aprea Therapeutics, Inc.
APRE evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $9.7M
- Lead Asset:
- APR-1051 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for APRE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APRE
Aprea Therapeutics, Inc. (APRE) is a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, with a lead WEE1 inhibitor (APR-1051) in Phase 1 and an ATR inhibitor (ATRN-119) in Phase 1/2a.
Key risk: Early-stage pipeline
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$9.7M
Cash Runway
—
Lead Asset
APR-1051 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Aprea Therapeutics, Inc..
Aprea Therapeutics, Inc. (APRE) is a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, with a lead WEE1 inhibitor (APR-1051) in Phase 1 and an ATR inhibitor (ATRN-119) in Phase 1/2a.
- Cash & equivalents of $41.2M as of 2026-06-30 [sec].
- Net loss of -$3.6M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $38.5M as of 2026-06-30 [sec].
- Lead candidate APR-1051 (oral WEE1 inhibitor) is in Phase 1 dose escalation (ACESOT-1051) with early single-agent activity and manageable tolerability [news · 2026-08-12].
- Second pipeline candidate ATRN-119 (Mosipasertib, oral ATR inhibitor) is in Phase 1/2a for advanced solid tumors [pipeline].
What works
- Cash position of $41.2M as of 2026-06-30 provides a multi-year runway for ongoing Phase 1 trials [sec].
- APR-1051 has shown early clinical activity (partial responses, stable disease) across multiple tumor types, supporting expansion into uterine serous carcinoma and platinum-resistant ovarian cancer [news · 2026-06-01].
- The company has two distinct, orally bioavailable pipeline candidates (WEE1 and ATR inhibitors) targeting complementary DNA damage response pathways [pipeline].
What to weigh
- The company reported a net loss of -$3.6M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- APR-1051 is still in early Phase 1; dose escalation and backfill expansion are not expected to complete until Q2 2027, with no approved product generating revenue [news · 2026-06-01].
- The WEE1 inhibitor space is competitive, with Zentalis (ZN-c3/Azenosertib) and AstraZeneca (AZD-1775/Adavosertib) also active [pipeline].
From the filings
Quoted directly from source documents.
APR-1051 Phase 1 dose escalation accelerating
“Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances”
News · August 12, 2026
APR-1051 early single-agent activity at ASCO 2026
“Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051”
News · August 12, 2026
Catalyst timeline
- 2023-01-09 · Phase 2 start for ATRN-119 — Phase 1/2a study of oral ATRN-119 in advanced solid tumors initiated.
- 2024-06-13 · Phase 1 start for APR-1051 — First-in-human Phase 1 study of APR-1051 in advanced solid tumors initiated.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — Both lead candidates are in Phase 1/2a; no approved products or revenue [pipeline].
- Cash burn rate — Net loss of -$3.6M in latest period; cash runway depends on spending pace [sec].
- Competitive WEE1 space — Zentalis and AstraZeneca have advanced WEE1 inhibitors [pipeline].
What to watch
- Updated interim Phase 1 data for APR-1051 to be presented at EORTC-NCI-AACR Symposium (ENA 2026) in November 2026 [news · 2026-09-22].
- Completion of dose escalation and backfill expansion for APR-1051 expected Q2 2027 [news · 2026-06-01].
- Progress of ATRN-119 (Mosipasertib) Phase 1/2a trial [pipeline].
- Any future financing or partnership announcements given cash burn [sec].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Aprea Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aprea Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.10 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.9%
- Days to cover
- 0.1
- Shares short
- 103,019
- Daily short volume (Apr 30, 2026)
- 23.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APRE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aprea Therapeutics, Inc.?
Aprea Therapeutics, Inc. (APRE) is a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, with a lead WEE1 inhibitor (APR-1051) in Phase 1 and an ATR inhibitor (ATRN-119) in Phase 1/2a.
What is Aprea Therapeutics, Inc.'s lead drug candidate?
Aprea Therapeutics, Inc.'s most advanced tracked candidate is APR-1051 (Phase 1) for Advanced Solid Tumor.
Who is the CEO of Aprea Therapeutics, Inc.?
Dr. Oren Gilad Ph.D. is the chief executive officer of Aprea Therapeutics, Inc. (APRE).
Where is Aprea Therapeutics, Inc. headquartered?
Aprea Therapeutics, Inc. (APRE) is headquartered in Doylestown, PA, United States.
What therapeutic areas does Aprea Therapeutics, Inc. focus on?
Aprea Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.